Regional Differences in the Phase III Meteor Study of Cabozantinib (CABO) Versus Everolimus (EVE) in Advanced Renal Cell Carcinoma (RCC)

被引：0
|
作者：
Mainwaring, Paul [1 ]
Tannir, Nizar M. [1 ]
Powles, Thomas [1 ]
Motzer, Robert J. [1 ]
Rolland, Frederic [1 ]
Gravis, Gwanaelle [1 ]
Staehler, Michael [1 ]
Rink, Michael [1 ]
Retz, Margitta [1 ]
Csoszi, Tibor [1 ]
McCaffrey, John A. [1 ]
De Giorgi, Ugo [1 ]
Caserta, Claudia [1 ]
Cheporov, Sergey [1 ]
Gonzalez, Emilio Esteban [1 ]
Duran, Ignacio [1 ]
Larkin, James G. [1 ]
Berg, William [1 ]
Clary, Douglas O. [1 ]
Escudier, Bernard [1 ]
Choueiri, Toni K. [1 ]
机构：
[1] Mater Med Ctr, ICON Canc Care, South Brisbane, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
183
引用
收藏
页码：129 / 130
页数：2
相关论文
共 50 条
  • [41] Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice
    Grassi, Paolo
    Verzoni, Elena
    Mennitto, Alessia
    Procopio, Giuseppe
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2016, 5 (06) : 974 - 976
  • [42] A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR)
    Choueiri, T. K.
    Escudier, B.
    Powles, T.
    Cella, D.
    Lee, Y.
    Laird, D. A.
    Scheffold, C.
    Motzer, R. J.
    BJU INTERNATIONAL, 2013, 112 : 4 - 4
  • [43] Cabozantinib (C) exposure-response (ER) modeling of safety endpoints in patients (pts) with renal cell carcinoma (RCC) in the phase III METEOR study.
    Lacy, Steven
    Hutmacher, Matthew M.
    Yang, Bei
    Motzer, Robert J.
    Escudier, Bernard J.
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [44] CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)
    Motzer, Robert J.
    Escudier, Bernard
    Mcdermott, David F.
    George, Saby
    Hammers, Hans J.
    Srinivas, Sandhya
    Tykodi, Scott S.
    Sosman, Jeffrey A.
    Procopio, Giuseppe
    Plimack, Elizabeth R.
    Castellano, Daniel
    Gurney, Howard
    Donskov, Frede
    Bono, Petri
    Wagstaff, John
    Gauler, Thomas C.
    Ueda, Takeshi
    Xu, Li-An
    Waxman, Ian M.
    Sharma, Padmanee
    BJU INTERNATIONAL, 2015, 116 : 17 - 17
  • [45] Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC)
    Whorf, R. C.
    Hainsworth, J. D.
    Spigel, D. R.
    Yardley, D. A.
    Burris, H. A., III
    Waterhouse, D. M.
    Vazquez, E. R.
    Greco, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).
    McGregor, Bradley Alexander
    Huang, Jiaming
    Xie, Wanling
    Xu, Wenxin
    Bilen, Mehmet Asim
    Braun, David A.
    Zhang, Tian
    McKay, Rana R.
    McDermott, David F.
    Hammers, Hans J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Cabozantinib as new Option for Renal Cell Carcinoma pretreated with TKI Final Results of the randomized Phase III Approval Study (METEOR)
    Boegemann, Martin
    ONKOLOGE, 2017, 23 (04): : 311 - 313
  • [48] Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study).
    de Souza, Paul L.
    Wong, Shirley
    Sewak, Sanjeev
    Kotasek, Dusan
    Keam, Bhumsuk
    Chung, Jinsoo
    Erbeck, Noelle
    Han, Jackie
    Dezzani, Luca
    Ahmad, Qasim
    Mainwaring, Paul N.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [49] Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC)
    Powles, Thomas
    Motzer, Robert J.
    Escudier, Bernard J.
    Pal, Sumanta K.
    Kollmannsberger, Christian K.
    Pikiel, Joanna
    Gurney, Howard
    Rha, Sun Young
    Park, Se Hoon
    Geertsen, Poul F.
    Gross-Goupil, Marine
    Grande, Enrique
    Suarez, Cristina
    Arroyo, Alan M.
    Dean, Mark
    George, Daniel
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Predictive and prognostic factors in a phase III study of pazopanib in patients with advanced renal cell carcinoma (RCC)
    Sternberg, C.
    Davis, I.
    Wagstaff, J.
    Hawkins, R.
    Chen, M.
    Ding, J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 424 - 424
12345